Compare Enovix Corporation (ENVX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs IDEXX Laboratories, Inc. — how do they compare? Enovix Corporation trades at $4.79 (market cap $1.11B), while IDEXX Laboratories, Inc. trades at $577.02 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 39.6× Enovix Corporation's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | IDXX | |
|---|---|---|
Market Cap | $1.11B | $43.94B |
Sector | Technology | Health |
52-Week High | $15.93 | $766.68 |
52-Week Low | $4.84 | $514.61 |
Enterprise Value | $1.13B | $44.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.855, down 4.05% today amid bearish technical signals. The company shows strong revenue growth potential with recent earnings beats but operates at a significant loss, reflected in a -499.64% net margin. Positive sentiment is driven by analyst consensus with a $12.75 price target and recent operational hires from Apple, though cash flow remains negative as production scales.
Outlook hinges on successful manufacturing ramp-up and smartphone battery qualification. High execution risk and cash burn present challenges, but leadership in silicon-anode technology offers long-term upside if commercial targets are met. Investors face volatility but potential reward from current discounted levels.
IDXX stock trades at $540.68, down 4.15% in the last session, with technical indicators showing a bearish bias. Fundamentally, the company demonstrates strong profitability with a 24.63% net margin and consistent earnings beats in recent quarters. Revenue growth continues, reaching $4.3B in 2025. Analyst sentiment remains predominantly positive with a 59% buy rating, though technical signals conflict with this fundamental strength.
The outlook balances robust fundamentals against technical weakness. Investment opportunity lies in sustained high profitability and market leadership in veterinary diagnostics, but risks include elevated valuation multiples (P/E 40.99) and bearish technical momentum that may pressure the stock near-term despite positive analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
